[Skip to Content]
[Skip to Content Landing]
November 7, 1977

Growth Velocity in a Child on Prolonged Hemodialysis: Beneficial Effect of 1-α-Hydroxyvitamin D3

Author Affiliations

From the Section on Steroid and Mineral Metabolism, Hypertension-Endocrine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md (Dr Chan), and the Department of Biochemistry, University of Wisconsin, Madison (Dr DeLuca).

JAMA. 1977;238(19):2053-2054. doi:10.1001/jama.1977.03280200065024

SECONDARY hyperparathyroidism, renal osteodystrophy, and growth failure nearly invariably develop in children on prolonged hemodialysis.1-3 We report our experience with a child who showed acceleration of growth velocity in response to treatment with the analogue (1-α-hydroxyvitamin D3) of the kidney hormone, 1,25 dihydroxyvitamin D3 (1,25-[OH]2-D3).

Report of a Case  An 11-year-old girl entered the hemodialysis program for irreversible end-stage kidney failure secondary to focal segmental glomerulosclerosis. Over the next four years, she received four to six hours of dialysis treatment three times per week on parallel flow and/or coil disposable dialyzers. Vascular access, dialysis procedures, delivery system, and dietary and antihypertensive therapy were identical to the standard methods previously reported from this unit.1,4,5 The caloric and protein intakes at 12,13, and 14 years of age are shown in the Table.Treatment with 1-α-hydroxyvitamin D3 (1-α-OH-D3) was initiated four months prior to